相似文献
1
Aminothiazolomorphinans with mixed κ and μ opioid activity.
J Med Chem. 2011 Mar 24;54(6):1903-13. doi: 10.1021/jm101542c. Epub 2011 Feb 25.
2
Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
J Med Chem. 2013 Nov 14;56(21):8872-8. doi: 10.1021/jm401290y. Epub 2013 Oct 29.
3
2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
J Med Chem. 2004 Apr 8;47(8):1886-8. doi: 10.1021/jm049978n.
4
Design and synthesis of novel dimeric morphinan ligands for kappa and micro opioid receptors.
J Med Chem. 2003 Nov 20;46(24):5162-70. doi: 10.1021/jm030139v.
5
Synthesis and binding affinity of novel mono- and bivalent morphinan ligands for κ, μ, and δ opioid receptors.
Bioorg Med Chem. 2011 May 1;19(9):2808-16. doi: 10.1016/j.bmc.2011.03.052. Epub 2011 Mar 26.
6
Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
J Med Chem. 2007 May 3;50(9):2254-8. doi: 10.1021/jm061327z. Epub 2007 Apr 4.
7
High-affinity carbamate analogues of morphinan at opioid receptors.
Bioorg Med Chem Lett. 2007 Mar 15;17(6):1508-11. doi: 10.1016/j.bmcl.2007.01.013. Epub 2007 Jan 17.
8
Mixed kappa agonists and mu agonists/antagonists as potential pharmacotherapeutics for cocaine abuse: synthesis and opioid receptor binding affinity of N-substituted derivatives of morphinan.
Bioorg Med Chem Lett. 2001 Oct 22;11(20):2735-40. doi: 10.1016/s0960-894x(01)00543-1.
9
Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
J Med Chem. 2006 Jan 12;49(1):256-62. doi: 10.1021/jm050577x.
10
Effects of substitution on the pyrrole N atom in derivatives of tetrahydronaltrindole, tetrahydrooxymorphindole, and a related 4,5-epoxyphenylpyrrolomorphinan.
J Med Chem. 2004 Dec 16;47(26):6645-8. doi: 10.1021/jm040817t.
引用本文的文献
1
Opioid Affinity of Diazacyclic Peptidomimetic Compounds Derived from Reduced Polyamides.
Int J Mol Sci. 2025 Aug 25;26(17):8249. doi: 10.3390/ijms26178249.
2
Peripherally Restricted Fused Heterocyclic Peptidomimetic Multifunctional Opioid Agonists as Novel, Potent Analgesics.
ACS Med Chem Lett. 2025 Feb 6;16(3):388-396. doi: 10.1021/acsmedchemlett.4c00333. eCollection 2025 Mar 13.
3
Novel multi-objective affinity approach allows to identify pH-specific μ-opioid receptor agonists.
J Cheminform. 2023 Sep 19;15(1):85. doi: 10.1186/s13321-023-00746-4.
4
Diels-Alder Adducts of Morphinan-6,8-Dienes and Their Transformations.
Molecules. 2022 Apr 30;27(9):2863. doi: 10.3390/molecules27092863.
5
Copper-Catalyzed Electrophilic Amination of Heteroaromatic and Aromatic C-H Bonds via TMPZnCl•LiCl Mediated Metalation.
Organic Synth. 2015;92:356-372. doi: 10.15227/orgsyn.092.0356. Epub 2015 Nov 17.
6
Copper-catalyzed electrophilic amination of heteroarenes and arenes by C-H zincation.
Angew Chem Int Ed Engl. 2014 Apr 25;53(18):4667-70. doi: 10.1002/anie.201311029. Epub 2014 Mar 25.
7
Synthesis and pharmacological evaluation of aminothiazolomorphinans at the mu and kappa opioid receptors.
J Med Chem. 2013 Nov 14;56(21):8872-8. doi: 10.1021/jm401290y. Epub 2013 Oct 29.
8
Synthesis, binding affinity, and functional in vitro activity of 3-benzylaminomorphinan and 3-benzylaminomorphine ligands at opioid receptors.
J Med Chem. 2012 Apr 26;55(8):3878-90. doi: 10.1021/jm3001086. Epub 2012 Apr 4.
本文引用的文献
1
Synthesis and biological evaluation of amidine, guanidine, and thiourea derivatives of 2-amino(6-trifluoromethoxy)benzothiazole as neuroprotective agents potentially useful in brain diseases.
J Med Chem. 2010 Jan 28;53(2):734-44. doi: 10.1021/jm901375r.
2
Low molecular weight non-peptide mimics of omega-conotoxin GVIA.
Bioorg Med Chem Lett. 2009 May 15;19(10):2763-5. doi: 10.1016/j.bmcl.2009.03.130. Epub 2009 Mar 28.
3
Novel cyano- and amidinobenzothiazole derivatives: synthesis, antitumor evaluation, and X-ray and quantitative structure-activity relationship (QSAR) analysis.
J Med Chem. 2009 Mar 26;52(6):1744-56. doi: 10.1021/jm801566q.
4
Pharmacological characterization of ATPM [(-)-3-aminothiazolo[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior.
J Pharmacol Exp Ther. 2009 Apr;329(1):306-13. doi: 10.1124/jpet.108.142802. Epub 2009 Jan 9.
5
In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
Bioorg Med Chem. 2007 Jun 15;15(12):4106-12. doi: 10.1016/j.bmc.2007.03.076. Epub 2007 Mar 30.
6
2-aminothiazole-derived opioids. Bioisosteric replacement of phenols.
J Med Chem. 2004 Apr 8;47(8):1886-8. doi: 10.1021/jm049978n.
7
10-Ketomorphinan and 3-substituted-3-desoxymorphinan analogues as mixed kappa and micro opioid ligands: synthesis and biological evaluation of their binding affinity at opioid receptors.
J Med Chem. 2004 Jan 1;47(1):165-74. doi: 10.1021/jm0304156.
8
SOME POTENT MORPHINE ANTAGONISTS POSSESSING HIGH ANALGESIC ACTIVITY.
J Med Chem. 1964 Mar;7:127-31. doi: 10.1021/jm00332a002.
9
Effects of mixed-action kappa/mu opioids on cocaine self-administration and cocaine discrimination by rhesus monkeys.
Neuropsychopharmacology. 2003 Jun;28(6):1125-39. doi: 10.1038/sj.npp.1300105. Epub 2003 Mar 5.
10
Microwave-promoted Pd-catalyzed cyanation of aryl triflates: a fast and versatile access to 3-cyano-3-desoxy-10-ketomorphinans.
Org Lett. 2003 Jan 23;5(2):201-3. doi: 10.1021/ol027256p.
Zotero 插件